Tracking bile duct and liver cancer during treatment
Part of Cancer, Digestive system clinical trials.
This study tracks how bile duct and liver cancers change during treatment, to help doctors find the best therapies for patients. It is for people who are newly diagnosed or starting a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have bile duct, gallbladder, or liver cancer that will be treated with surgery, medication, or other therapies.
- You are able to understand and follow the study information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
This study looks at tissue samples from people with bile duct, liver, or pancreas problems to develop better ways to detect cancers in these areas. If you are scheduled for a biopsy, scan, or surgery for a suspected growth in your liver, pancreas, or bile duct, you may be able to help.
This trial uses a simple blood test to track how well bile duct cancer responds to treatment and to predict outcomes. It may help doctors make better decisions about surgery and other therapies.
This study aims to improve how doctors diagnose and treat liver cancer by combining advanced imaging tests and genetic analysis. It may help in choosing the most effective treatment for each person.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study is collecting information and blood samples from people with biliary tract cancer to understand how certain markers and quality-of-life measures relate to treatment outcomes. The findings may help improve future care and support.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.